developing meningeal carcinomatosis was 2.7% at three years and 7.8% at five years.
[1] It spreads mainly by hematogenous route and CSF is diagnostic. 30-60% have co-existent parenchymal brain metastasis. Treatment is Intrathecal Chemotherapy -Methotrexate, Cytarabine, Thiotepa.
[2] Intrathecal Gemcitabine has been used in non small cell lung cancer.
[3] Intravenous teniposide may be used along with intrathecal chemotherapy.
[4] Involved field radiotherapy is reserved for bulky metastatic disease.
The presentation of meningeal carcinomatosis without systemic metastases is rare. Our patient had a metastatic lung nodule to begin with but the disease was well controlled at the time of presentation with meningeal carcinomatosis. The symptoms of headache, vomiting with raised blood pressure along with normal imaging led to a delay in doing CSF cytology. Meningeal carcinomatosis may prove difficult to diagnose as imaging may be misleading. This warrants a high index of suspicion and early CSF cytology. 
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Perspectives on QOL in India
Dear Sir, This is a letter in response to an article in your latest issue. [1] This is a nice article on QOL that deserves credit. I would like to congratulate the Editorial team of IJC for taking the initiative in publishing such articles on QOL.
The impact of HNC and its treatment can have a profound effect on the patients' physical function and psychological wellbeing and it is essential that their perspective is taken into account. Questionnaires give a structured snapshot or insight into the patients' point of view. They facilitate multidisciplinary team working with the recognition of poor outcome groups, better in formation for the patients and their careers, and the opportunity to identify problem areas and target intervention/support. QOL is a neglected domain in our country. But if we want to compete with the West, we must try and focus on this area where we are at least 10 to 15 years behind.
The authors have taken great pain to bring out this article. I was especially happy and impressed with the honest efforts at the translation process. However we must keep in mind certain important points that are necessary for a balanced perspective.
The UW-QOL scale is brief and simple scale that arms the clinicians with useful information and can contribute to decision-making based on patient feedback. Moreover, it concerns issues that have been important in the last seven days which are easy to recollect. In addition, it can help in audit, research and assist in the making of patient information leaflets/videos.
The availability of open-ended text in the scale, albeit as a single item, provides yet another avenue of information regarding individual patients. However issues such as speech, saliva, smell, cough and mucous production were not addressed adequately in the questionnaire. This raises an important issue that existing QOL instruments may not be sensitive or specific enough for the especially Letter to Editor
Pulmonary artery sarcoma: The hidden truth
Dear Sir, An important case report on the Pulmonary artery sarcoma was published in the January-March 2008 issue of the journal.
[1] I agree with the authors that the pulmonary artery sarcoma is a rare entity but in year 2008 itself, at least eleven articles could be found on medline. It is not true that these types of tumors are rare but their diagnosis may be confusing. There is no doubt that PET scan may prove to be beneficial but at the same time echocardiography may also help in detection of the tumor. Dyspnea may be the most common presenting symptom. Progressive dyspnea and weight loss may be important findings which should not be overlooked.
[2] Proper physical examination findings were found to be lacking in this case. Heart rate, blood
Authors' reply
Dear Sir, In response to the editorial of our recently published case report "Pulmonary artery sarcoma mimicking a pulmonary embolism", [1] we would first like to thank the Dr. Das [2] for his interest in this case. We agree with his insight that these sarcomas are perhaps not as rare as historically documented. Rather, the rarity is attributable to the challenge involved in making the diagnosis. In fact, this point is emphasized by the fact that symptoms (shortness of breath, dyspnea, and chest pain), physical examination (heart rate, blood pressure, respiratory rate, and the presence of cyanosis), and imaging studies (computed tomography and echocardiography) can all be indistinguishable from a pulmonary embolism. We agree with the editorial that all of these factors are important; however, none of them are able to distinguish between an embolism and a sarcoma. A PET scan can be a modality that could help identifying this masquerader as a malignancy, just shy of performing an invasive biopsy. Our goal was to convey the importance of considering a PET scan when confronted with such a scenario, which hopefully we were successful in doing. pressure, respiratory rate and presence of any cyanosis should have been explored properly.
